
Small biotech — big ambitions. Viralytics’ oncolytics therapy makes the showcase round at #AACR17 with positive combo snapshot
PHOTO: © AACR/Todd Buchanan 2017
WASHINGTON, DC — When you talk to Viralytics CEO Malcolm McColl, he has a habit of reminding his listeners about just how small his public Australian biotech is. Small staff, small studies. And there are just so many things a small biotech can do.
But he and his company {ASX: VLA} have some very big ambitions in the hot oncolytics field, building their hopes around a therapy called Coxsackievirus A21 (or CVA21 or Cavatak). And today the powers that be at AACR are steering their latest data into the showcase morning round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.